Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005674 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]
A Phase 2 study, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005674 is a Phase 2 study that has completed, run by National Center for Research Resources (NCRR).
The verdict
NCT00005674, a Phase 2 study, has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of creatine treatment in amyotrophic lateral sclerosis (ALS). There is currently no known effective treatment for ALS. It is known that nerve cells die in the brains and spinal cords of patients with ALS but the cause of the cell death is unknown. It has been shown that there is overactive nerve activity due to increased levels of a chemical called glutamate and that there is abnormal cellular metabolism along with increased production of substance called "free radicals." Improving cellular metabolism and readjusting the activity of glutamate in the brain may be beneficial to ALS patients. Creatine is a naturally occurring compound, which improves energy metabolism in cells. Creatine has been given to patients with energy metabolism defects in their muscles, and to athletes. Creatine improves survival in a mouse model of ALS. Three human subjects with ALS have received creatine for up to six months without any side effects. Overall, creatine has been well tolerated and safe.
Interventions
- DRUG Creatine
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005674
The ClinicalTrials.gov registry entry for NCT00005674 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Center for Research Resources (NCRR), which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Creatine is the first listed.
NCT00005674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005674 about?
NCT00005674 is a clinical study titled "Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]". The purpose of this study is to evaluate the safety and effectiveness of creatine treatment in amyotrophic lateral sclerosis (ALS). There is currently no known effective treatment for ALS. It is known that nerve cells die in the brains and spinal cords of patients with ALS but the cause of the cell ...
What is the current status of trial NCT00005674?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00005674?
The interventions under investigation include: Creatine (DRUG).
Who is sponsoring clinical trial NCT00005674?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.